Skip to main content

Advertisement

Table 1 Performance of the classifier. Performance of the 13 clusters classifier algorithm re-training and validation on the separate institutional populations using both leave-one-out and multiple 10-fold cross-validations.

From: Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

Training set (total/events) Validation set (total/events) Hazard ratio (95%CI) Log rank p value Distant Metastases Free Survival for low risk group only#
     DMFS at 3 years DMFS at 5 years DMFS at 10 years
OXFT (99/19) KIT/GUYT(156/48) 2.17 (1.2–3.91) <0.00001 91% 87% 79%
KIT (69/20) OXFT/GUYT (186/47) 4.07 (2.23–7.41) <0.00001 96% 92% 88%
GUYT (87/28) OXFT/KIT (168/39) 5.93 (3.0–11.75) <0.00001 93% 89% 82%
KIT/GUYT (156/48) OXFT (99/19) 14.59 (5.38–39.5) <0.00001 97% 94% 91%
OXFT/GUYT (186/47) KIT (69/20) 3.44 (1.36–8.67) 0.005 96% 92% 84%
OXFT/KIT(168/39) GUYT (87/28) 2.23 (1.05–4.71) 0.03 96% 92% 84%
Leave-one-out cross validation (255/67)* 3.86 (2.32–6.41) <0.0001 94% 91% 84%
Multiple 10-fold cross-validation (255/67) 3.23 (2.66–3.84) <0.0001 94% 90% 83%
  1. # as estimated by Kaplan Meier survival curves.
  2. Patients samples obtained from: OXFT: John Radcliffe Hospital, Oxford, UK; KIT Uppsala University hospital, Uppsala, Sweden; GUYT Guys hospital, London, UK.
  3. • Reported results.